The theses of the study confirming the antioxidant properties of Mexidol® are accepted by the European Society of Cardiology (ESC)

The results of the study of the effect of Mexidol® (2-ethyl-6-methyl-3-hydroxypyridine succinate) on oxidative stress in patients with decompensated heart failure and cognitive impairment are published on the website of the European Society of Cardiology, https://www.escardio.org/Search/?q=Mexidol&filters:content_type=ESC365%20Presentation. The purpose of the study was to evaluate the effect of Mexidol® on the level of oxidative stress markers (malondialdehyde*, superoxide dismutase**, glutathione peroxidase***), plasma antioxidant activity in patients with decompensated heart failure and cognitive impairment. Oxidative stress markers were investigated at the beginning of therapy and after its completion. Patients treated with Mexidol® showed a significant decrease in the level of malondialdehyde – by 20.77% (p=0.02) and a significant increase – by 20.68% – in the level of glutathione peroxidase (p=0.04), as well as a tendency to increase the level of superoxide dismutase by 43.43% and plasma antioxidant activity by 42.69%.

Thus, the study showed a marked antioxidant effect of Mexidol® in patients with decompensated heart failure and cognitive impairment.

Note:

*Malondialdehyde is an endogenous aldehyde, which is a clinical and laboratory oxidative stress marker used to predict and control the treatment of a wide range of diseases, including heart failure.

**Superoxide dismutase is one of the main intracellular antioxidant protection enzymes catalyzing the decomposition of superoxide into oxygen and hydrogen peroxide. It takes an important part in the antioxidant protection of almost all cells.

***Glutathione peroxidase is one of the main intracellular antioxidant enzymes catalyzing restoration of lipid hydroperoxides into alcohols and restoration of hydrogen peroxide to the state of water.